Recursion Pharmaceuticals vs Doximity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.
About
Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.
Doximity (NYSE: DOCS), professional network for US physicians with 2M+ verified clinicians; telehealth, medical news, and career tools monetized via pharmaceutical digital marketing.
About
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinicians on the platform — representing the majority of practicing US physicians — Doximity has established itself as the dominant professional network for doctors, providing identity-verified peer connections, specialty-specific news feeds, medical journal access, and career management tools including a physician job board and CV builder. The verification layer distinguishes Doximity from general professional networks and makes it the standard reference for confirming physician credentials and contact information across the healthcare industry.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.